Clinical trial
Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic…
NCT00003808 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003808 |
|---|---|
| Title | Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Theophylline in Chronic Lymphocytic Leukemia |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH North Central Cancer Treatment Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | theophylline |
| Start date | Aug 11, 1999 |
| Primary completion | Sep 1, 2002 |
| First posted | Jul 22, 2004 |
| Last update posted | Jun 22, 2023 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: